High priorities: sustainability & continual improvement
Actavis Completes Forest Laboratories Acquisition

R&D Sites

20+ R&D facilities focused on generics, brands and biosimilars

Actavis has more than 20 global R&D facilities focused on identifying and pursuing global product development opportunities in generics, brands and biosimilars.

Research and development activities capitalize on the Company’s expertise in numerous drug delivery technologies, including solid dosage from, oral-controlled and sustained release, semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies and the application of these technologies to proprietary drug forms.

Working at Actavis
Actavis is a dynamic, forward-thinking organization that offers exciting and unique opportunities at all levels across our Company.